Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 395

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Dreyling, Martin, Santoro, Armando, Mollica, Luigina, Leppä, Sirpa, Follows, George A., Lenz, Georg, Kim, Won Seog, Nagler, Arnon, Panayiotidis, Panayiotis, Demeter, Judit, Özcan, Muhit, Kosinova, Marina, Bouabdallah, Krimo, Morschhauser, Franck, Stevens, Don A., Trevarthen, David, Giurescu, Marius, Cupit, Lisa, Liu, Li, Köchert, Karl, Seidel, Henrik, Peña, Carol, Yin, Shuxin, Hiemeyer, Florian, Garcia-Vargas, Jose, Childs, Barrett H., Zinzani, Pier Luigi·2017·Journal of Clinical Oncology

Abstract

Purpose: Phosphatidylinositol 3-kinase (PI3K) signaling is critical for the proliferation and survival of malignant B cells. Copanlisib, a pan-class I PI3K inhibitor with predominant activity against PI3K-α and -δ isoforms, has demonstrated efficacy and a manageable safety profile in patients with indolent lymphoma. Patients and Methods: In this phase II study, 142 patients with relapsed or refractory indolent lymphoma after two or more lines of therapy were enrolled to receive copanlisib 60 mg intravenously on days 1, 8, and 15 of a 28-day cycle. The primary end point was objective response rate; secondary end points included duration of response, progression-free survival, and overall survival. In addition, safety and gene expression were evaluated. Results: Median age was 63 years (range, 25 to 82 years), and patients had received a median of three (range, two to nine) prior regimens. The objective response rate was 59% (84 of 142 patients); 12% of patients achieved a complete response. Median time to response was 53 days. Median duration of response was 22.6 months, median progression-free survival was 11.2 months, and median overall survival had not yet been reached. The most frequent treatment-emergent adverse events were transient hyperglycemia (all grades, 50%; grade 3 or 4, 41%) and transient hypertension (all grades, 30%; grade 3, 24%). Other grade ≥3 events included decreased neutrophil count (24%) and lung infection (15%). High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes. Conclusion: PI3K-α and -δ inhibition by copanlisib demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.75.4648

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 395

Metadata

Authors
Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Bouabdallah, K., Morschhauser, F., Stevens, D. A., Trevarthen, D., Giurescu, M., Cupit, L., Liu, L., Köchert, K., Seidel, H., Peña, C., Yin, S., Hiemeyer, F., Garcia-Vargas, J., Childs, B. H., & Zinzani, P. L.
Venue
Journal of Clinical Oncology
Published
2017-12-10
Volume
35
Issue
35
Pages
3898-3905
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2762226752
Cited by
395
References
23
FWCI
25.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2017.75.4648
The paper
Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Bouabdallah, K., Morschhauser, F., Stevens, D. A., Trevarthen, D., Giurescu, M., Cupit, L., Liu, L., . . . Zinzani, P. L. (2017). Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.75.4648

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.